Lasrekibart is a humanized monoclonal antibody targeting human interleukin-5 (IL-5). It specifically binds to IL-5 and blocks its interaction with the receptor, thereby exerting immunosuppressive and anti-inflammatory effects. Lasrekibart holds potential for research into allergic and inflammatory diseases, such as asthma.